A comprehensive review article has just been published, titled JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.
The article discusses the merits of four JAK inhibitors, three of which are available to Australian patients on the PBS (ruxolitinib, momelotinib and fedratinib).
The abstract explains that “JAK inhibitors have transformed [myelofibrosis] management by providing symptom relief and reducing spleen size in many patients.” It explains that each JAK inhibitor has “distinct profiles and safety considerations that may inform selection…… therefore, first-line selection and optimal sequencing in particular patients can be challenging.”
“This review summarizes the current data surrounding available JAK inhibitors for the treatment of patients with myelofibrosis and examines how individual patients’ characteristics can help guide selection among them.”
We are most fortunate that this review article is in the journal haematologica, so it is free to access. JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.
